Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Oral Treatment Regimen Achieves 90% Sustained Virologic Response

November 9, 2011 11:31 am | News | Comments

Bristol-Myers Squibb  announced results from a 10- patient sentinel cohort of an ongoing Phase 2 study in which treatment with a dual, all-oral direct-acting antiviral regimen of the investigational NS5A replication complex inhibitor daclatasvir and the investigational NS3 protease inhibitor asunaprevir achieved undetectable viral load.

NY Genome Center, 11 Others Collaborate

November 9, 2011 11:26 am | News | Comments

The New York Genome Center launched a collaborative venture in genomic medicine with eleven private and academic medical centers.


Corkscrew Mechanism May Provide Cancer Therapy

November 9, 2011 11:19 am | News | Comments

Scientists from the universities of Zurich and Duisburg-Essen discovered a specific function of the protein p97/VCP, demonstrating that the protein repairs DNA breaks like a corkscrew.


How Brain Cells Degrade Protein Aggregates

November 9, 2011 11:15 am | News | Comments

Researchers at the Riken Brain Science Institute have discovered a mechanism responsible for selectively degrading aggregates of ubiquitinated proteins from the cell.


Study Challenges Approaches to Alzheimer’s Research

November 9, 2011 11:12 am | News | Comments

Although intensely investigated over the last three decades, the pathogenic cause of Alzheimer’s disease has not been found.


Stroke Factors May Lead to Cognitive Problems

November 9, 2011 11:08 am | News | Comments

High blood pressure and other known risk factors for stroke increase the risk of developing cognitive problems, a study funded by the National Institutes of Health has found.


Scientist Awarded Grant to Study Parkinson Disease

November 9, 2011 11:05 am | News | Comments

The Scripps Research Institute has been awarded a $500,000 grant by the Michael J. Fox Foundation to study a pair of genetic mutations that could lead to a potential therapeutic target for Parkinson’s disease.


MRI for Developing Brain Reports Undetectable Injuries

November 9, 2011 11:00 am | News | Comments

Pediatric neuroscientists at Oregon Health Science University Doernbecher Children’s Hospital used a high magnetic field strength MRI to reveal tiny white matter injuries in the developing brain previously undetectable using standard MRI.


Mouse Model Developed to Study Alzheimer’s

November 9, 2011 10:56 am | News | Comments

In research at the University of Georgia, a cellular biologist and his colleagues have found that Hirano bodies may play a protective role in the progression of neurodegenerative diseases such as Alzheimer's.


Alzheimer Disease Center Receives Dementia Funding

November 9, 2011 10:39 am | News | Comments

The National Institutes of Health has renewed funding to the Indiana Alzheimer Disease Center at Indiana University School of Medicine for the fifth consecutive five-year term, awarding the center a grant of $9.1 million.


Culture Protocols

November 9, 2011 7:08 am | Product Releases | Comments

3D Biomatrix has developed protocols to precisely calibrate the Beckman Coulter Biomek FX laboratory automation workstation software for use with Perfecta3D hanging drop plates.


Plasmid Screening

November 9, 2011 6:54 am | Product Releases | Comments

G­Biosciences' Toothpick systems allow for the rapid screening of bacterial colonies by restriction enzyme digestion analysis or polymerase chain reaction, with the Plasmid Screening Toothpick and Toothpick­PCR, respectively.


Battelle Working with Molecular Imaging

November 9, 2011 6:42 am | News | Comments

Battelle has enhanced its drug discovery and development services through a collaboration with Molecular Imaging Inc., a specialty provider of small-scale nonclinical in vivo multi-modality imaging services.


Warner Chilcott Buying Back $250M in Stock

November 9, 2011 6:37 am | News | Comments

Irish drugmaker Warner Chilcott PLC said its board has authorized the redemption of up to $250 million in stock. The buybacks will be made through the open market or privately negotiated purchases with cash generated from operations.


Positive Data from Drug Dependence Study

November 9, 2011 6:30 am | News | Comments

Alkermes plc presented positive results from a long-term study of Vivitrol that showed sustained efficacy, as measured by the number of opioid-free urine screens, in patients who received Vivitrol.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.